专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20100041032A1 COMPOSITION AND METHODS FOR THE DETECTION OF CRIPTO-3 审中-公开
标题翻译：用于检测CRIPTO-3的组合物和方法
公开(公告)号：US20100041032A1
公开(公告)日：2010-02-18
申请号：US12298875
申请日：2007-04-30
申请人： Olivia Orozco , Michele Sanicola-Nadel , Eugene Choi , John Carulli , Richard Tizard , Suzanne Szak , Chao Sun
发明人： Olivia Orozco , Michele Sanicola-Nadel , Eugene Choi , John Carulli , Richard Tizard , Suzanne Szak , Chao Sun
IPC分类号： C12Q1/68 , C12P21/08 , C07K16/00 , C07H21/04
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136
摘要： The present invention is based, at least in part, on the discovery that the pseudogene TDGF3 (Cripto-3) is expressed in cells and, in particular, that TDGF3 overexpression is associated with transformation of a cell, e.g., TDGF3 is overexpressed in cancer cell lines and cells from tumor tissue. Accordingly, the invention provides compositions, kits, and methods for detecting the presence of a TDGF3 polynucleotide or polypeptide in a sample. The invention further provides compositions, kits and methods for assessing whether a cell is transformed as well as for assessing whether a patient is a suitable candidate for an anti-Cripto antibody therapy.
摘要翻译：本发明至少部分地基于在细胞中表达假性TDGF3（Cripto-3）的发现，特别是TDGF3过表达与细胞的转化相关，例如TDGF3在癌症中过表达来自肿瘤组织的细胞系和细胞。因此，本发明提供用于检测样品中TDGF3多核苷酸或多肽的存在的组合物，试剂盒和方法。本发明还提供用于评估细胞是否被转化以及评估患者是否是抗Cripto抗体治疗的合适候选者的组合物，试剂盒和方法。

72. 发明申请

US20100015131A1 Composition Comprising Antibodies to LINGO or Fragments Thereof 有权
标题翻译：包含LINGO或其片段的抗体的组成
公开(公告)号：US20100015131A1
公开(公告)日：2010-01-21
申请号：US12500472
申请日：2009-07-09
申请人： Sha MI , R. Blake Pepinsky
发明人： Sha MI , R. Blake Pepinsky
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , C12N5/00 , C12P21/04 , A61P25/00
CPC分类号： C07K16/2803 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/6849 , A61K47/6879 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/21 , C07K2317/35 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/01
摘要： Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody
摘要翻译：内源性LINGO-1是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。阻断内源性LINGO-1功能的分子，如抗LINGO-1抗体可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。本发明提供对LINGO-1特异性的抗体，以及使用这些抗体作为内源性LINGO-1功能的拮抗剂的方法。本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，包括对需要这种治疗的脊椎动物施用有效量的抗LINGO-1抗体

73. 发明申请

US20090324602A1 ANTI-FN14 ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：抗FN14抗体及其用途
公开(公告)号：US20090324602A1
公开(公告)日：2009-12-31
申请号：US12463291
申请日：2009-05-08
申请人： Ellen Garber , Linda Burkly , Jennifer Michaelson , Alexey Lugovskoy , Yen-Ming Hsu , Karl Hanf
发明人： Ellen Garber , Linda Burkly , Jennifer Michaelson , Alexey Lugovskoy , Yen-Ming Hsu , Karl Hanf
IPC分类号： A61K39/395 , C07K16/00 , C12N5/16 , C12N5/02
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/92
摘要： Antibodies and antibody fragments that bind to the receptor Fn14 and induce or enhance cell killing of Fn14-expressing cancer cells are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a tumor cell and treat disorders and in a subject.
摘要翻译：公开了结合受体Fn14并诱导或增强表达Fn14的癌细胞的细胞杀伤的抗体和抗体片段。还公开了使用抗体和抗体片段诱导肿瘤细胞死亡并治疗病症和受试者的方法。

74. 发明授权

US07638327B2 BAFF receptor antibodies and methods 失效
标题翻译： BAFF受体抗体和方法
公开(公告)号：US07638327B2
公开(公告)日：2009-12-29
申请号：US11426236
申请日：2006-06-23
申请人： Christine M. Ambrose , Jeffrey S. Thompson
发明人： Christine M. Ambrose , Jeffrey S. Thompson
IPC分类号： A61K39/395 , C12N5/12 , C07K16/28 , G01N33/563 , G01N33/567 , G01N33/577
CPC分类号： C07K14/70578 , A61K38/00 , A61K48/00 , C07H21/04 , C07K14/7151 , C07K16/2866 , C07K16/2878 , C07K2319/00 , Y02A50/414
摘要： Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.
摘要翻译：公开了编码BAFF-R多肽的核酸，以及对BAFF-R多肽的抗体和包含其的药物组合物。还提供了使用本发明的核酸，多肽，抗体和药物组合物治疗致瘤性和自身免疫病症的方法。

75. 发明授权

US07635466B1 DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon-like polypeptides 失效
标题翻译： DNA序列，重组DNA分子和用于产生人成纤维细胞干扰素样多肽的方法
公开(公告)号：US07635466B1
公开(公告)日：2009-12-22
申请号：US08452658
申请日：1995-05-25
申请人： Walter Charles Fiers
发明人： Walter Charles Fiers
IPC分类号： A61K38/21
CPC分类号： C07K14/005 , A61K38/00 , C07K14/565 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C07K2319/75 , C12N15/52 , C12N15/62 , C12N15/73 , C12N2710/22022
摘要： DNA sequences, recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying a biological or immunological activity of human fibroblast interferon, the genes coding for these polypeptides and methods of making and using these DNA sequences, molecules, hosts, genes and polypeptides. The DNA sequences are characterized by in that they code for a polypeptide displaying a biological or immunological activity of human fibroblast interferon. In appropriate hosts these DNA sequences and recombinant DNA molecules permit the production and identification of genes and polypeptides displaying a biological or immunological activity of human fibroblast interferon and their use in antiviral and antitumor or anitcancer agents.
摘要翻译： DNA序列，重组DNA分子和用它们转化的宿主，其产生显示人成纤维细胞干扰素的生物学或免疫学活性的多肽，编码这些多肽的基因以及制备和使用这些DNA序列，分子，宿主，基因和多肽的方法。 DNA序列的特征在于它们编码显示人成纤维细胞干扰素的生物学或免疫学活性的多肽。在适当的宿主中，这些DNA序列和重组DNA分子允许产生和鉴定展示人成纤维细胞干扰素的生物学或免疫学活性的基因和多肽及其在抗病毒和抗肿瘤或抗癌剂中的用途。

76. 发明申请

US20090291088A1 THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS 审中-公开
标题翻译：抗IGF-1R抗体和其他化合物的治疗组合
公开(公告)号：US20090291088A1
公开(公告)日：2009-11-26
申请号：US12422045
申请日：2009-04-10
申请人： Kandasamy Hariharan , Jianying Dong
发明人： Kandasamy Hariharan , Jianying Dong
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/2863 , C07K2317/20 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/30
摘要： The invention relates to methods of treatment using combination therapy wherein a variety of therapeutically useful compounds may be combined with antibodies which bind to insulin-like growth factor receptor-1 (IGF-1R). Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention particularly includes methods of treating cancer using combination therapies with IGF-1R antibodies.
摘要翻译：本发明涉及使用联合治疗的治疗方法，其中各种治疗有用的化合物可与与胰岛素样生长因子受体-1（IGF-1R）结合的抗体组合。提供了抑制IGF-1R介导的原始存活和肿瘤增殖途径的特异性人和鼠单克隆抗体及其变体，片段及其衍生物。还提供阻断配体，胰岛素样生长因子1（IGF-1）和胰岛素样生长因子2（IGF-2）与IGF-1R结合的能力的特异性人和鼠单克隆抗体，以及片段，这些抗体的变体和衍生物。本发明还包括编码上述抗体或其片段，变体或衍生物的多核苷酸，以及包含这种多核苷酸的载体和宿主细胞。本发明特别包括使用与IGF-1R抗体的组合疗法治疗癌症的方法。

77. 发明申请

US20090252725A1 Use of CD23 Antibodies to Treat Malignancies in Patients with Poor Prognosis 审中-公开
标题翻译：使用CD23抗体治疗不良预后患者的恶性肿瘤
公开(公告)号：US20090252725A1
公开(公告)日：2009-10-08
申请号：US12400695
申请日：2009-03-09
申请人： Sarah Harris , Shabnam Tangri
发明人： Sarah Harris , Shabnam Tangri
IPC分类号： A61K39/395 , C12N5/06
CPC分类号： C07K16/2887 , A61K39/39558 , A61K2039/505 , A61K2039/507 , C07K16/2851 , A61K2300/00
摘要： The invention relates to methods of treating B-cell chronic lymphocytic leukemia, and other CD23+ malignancies, in patients with poor prognostic markers. The method comprises administration of an CD23 antibody, including for example, lumiliximab to a mammal that over expresses a poor prognostic marker. The method can also comprise administration of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab. Patients with poor prognostic markers include, for example, patients that overexpress ZAP70, CD38, β2-microglobulin and/or soluble CD23.
摘要翻译：本发明涉及在不良预后标志物的患者中治疗B细胞慢性淋巴细胞性白血病及其他CD23 +恶性肿瘤的方法。该方法包括向过表达不良预后标志物的哺乳动物施用CD23抗体，包括例如lumiliximab。该方法还可以包括与氟达拉滨，环磷酰胺和利妥昔单抗组合施用lumiliximab。具有不良预后标志物的患者包括例如过表达ZAP70，CD38，β2-微球蛋白和/或可溶性CD23的患者。

78. 发明授权

US07585946B2 Active lymphotoxin-β receptor immunoglobulin chimeric protein compositions 有权
标题翻译：活性淋巴毒素-β受体免疫球蛋白嵌合蛋白组合物
公开(公告)号：US07585946B2
公开(公告)日：2009-09-08
申请号：US09767370
申请日：2001-01-23
申请人： Jeffrey Browning , Konrad Miatkowski , Werner Meier
发明人： Jeffrey Browning , Konrad Miatkowski , Werner Meier
IPC分类号： C07K14/52
CPC分类号： C12P21/00 , A61K38/00 , C07K14/70578 , C07K14/7151 , C07K2319/00 , C12P21/02
摘要： Methods for high level expression of active lymphotoxin-β receptor immunoglobulin chimeric proteins and their purification.
摘要翻译：高水平表达活性淋巴毒素-β受体免疫球蛋白嵌合蛋白的方法及其纯化。

79. 发明申请

US20090221821A1 ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME 审中-公开
标题翻译：腺苷受体拮抗剂及其制备和使用方法
公开(公告)号：US20090221821A1
公开(公告)日：2009-09-03
申请号：US12368469
申请日：2009-02-10
申请人： Carol L. Ensinger , James E. Dowling , Russell C. Petter , Gnanasambandam Kumaravel
发明人： Carol L. Ensinger , James E. Dowling , Russell C. Petter , Gnanasambandam Kumaravel
IPC分类号： C07D473/04
CPC分类号： C07D473/06 , C07D473/22 , C07F9/65616
摘要： The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.In one embodiment, the invention features a compound of formula I:
摘要翻译：本发明基于以下发现：式I化合物是意想不到的高度有效和选择性的腺苷A1受体抑制剂。腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环系统疾病，中枢神经系统的退行性疾病，呼吸系统疾病以及适合利尿治疗的许多疾病。在一个实施方案中，本发明的特征在于式I的化合物：

80. 发明授权

US07582299B2 Cripto-specific antibodies 有权
标题翻译： Cripto特异性抗体
公开(公告)号：US07582299B2
公开(公告)日：2009-09-01
申请号：US10945853
申请日：2004-09-20
申请人： Michele Sanicola-Nadel , Heather Adkins , Steven Donald Miklasz , Paul Rayhorn , Susan Gail Schiffer , Kevin P. Williams
发明人： Michele Sanicola-Nadel , Heather Adkins , Steven Donald Miklasz , Paul Rayhorn , Susan Gail Schiffer , Kevin P. Williams
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/30 , A61K2039/505 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C07K2319/30
摘要： The invention provides Cripto-specific antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and inhibit Cripto activity are provided. Antibodies which bind Cripto and inhibit the interaction between Cripto and ALK4 and/or between Cripto and Activin B are provided. Antibodies which bind Cripto and inhibit tumor growth are also provided. Antibodies which bind Cripto, inhibit Cripto activity, and inhibit tumor growth are also provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
摘要翻译：本发明提供了Cripto特异性抗体或其生物功能性片段及其用途。提供了结合Cripto并抑制Cripto活性的抗体。提供了结合Cripto并抑制Cripto和ALK4和/或Cripto和激活素B之间的相互作用的抗体。还提供了结合Cripto并抑制肿瘤生长的抗体。还提供了结合Cripto，抑制Cripto活性和抑制肿瘤生长的抗体。本发明还提供了在治疗，诊断和研究应用中使用这些抗体的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式